GSK, Sanofi anti-coagulant deal

GlaxoSmithKline (LSE:GSK; GSK) will pay EUR 453 million ($547.7 million) in cash to Sanofi- Synthelabo (Euronext:SAN; SNY) for global rights to Fraxiparine nadroparine low molecular weight heparin and Arixtra fondaparinux synthetic Factor Xa inhibitor, both injectable anti-coagulants. SAN began the divestiture program for these products in January, when the company announced its intentions to acquire Aventis (AVE). Closing of the deal with GSK is conditional upon the successful completion of SAN's offer for AVE, which AVE's board opposes. ...